ArticleBMC complementary medicine and therapies2025
Targeting the Parkinson's disease using sim (Rhodomyrtus tomentosa) fruit water extract.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- In Vitro Antioxidant Activity and In Vivo Neuroprotective Effect ofAntioxidants (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Parkinson's disease (PD) is a progressive nervous system disorder characterized by dysfunction or degeneration of dopaminergic neurons in the substantia nigra leading to motor symptoms. Parkinson's disease is more common in the elderly and severely reduces quality of life. There has been no cure for PD, the therapy is mainly based on symptomatic treatment. Because of the strong relationship between oxidative stress and PD, antioxidant compounds have been considered a novel therapy for PD treatment. However, long-term treatment with a compound may cause potential risks and adverse effects. Consequently, screening natural compounds with therapeutic properties has elicited significant interest, thereby contributing to the expansion of the pharmacological source for disease treatment.Sim (Rhodomyrtus tomentosa) is one kind of shrub, that belongs to the Myrtaceae family and has been used for a long time in traditional medicine of many Asian countries. All parts of sim can be used as medicine such as berried sim for treatment of diarrhea, and dysentery; leaves for wound healing, and roots for stomach cure. Previous studies suggested that sim fruit is rich in fiber, minerals, antioxidants, and anti-neurotoxic compounds. Utilizing antioxidant compounds from natural plants for PD therapy recently attracted attention. Because of its advantages, sim fruit has been supposed to be a potential candidate for drug screening. No scientific evidence has been reported proving sim fruit's PD treatment capacity. This study thus aimed to evaluate the potential of the sim fruit water extract (SFWE) for PD treatment using the dUCH knockdown Drosophila melanogaster model which owns hallmark PD symptoms such as dopaminergic neuron degeneration and locomotor dysfunction. Our results showed that SFWE has a strong antioxidant capacity with an IC50 value of 55.55 ± 2.012 µg/mL. As expected, when treated with SFWE at 1.25 mg/mL, ROS induced by knockdown of dUCH specifically at dopaminergic neurons (DA) were reduced. Notably, the degeneration of DA neurons on the PD fly model was ameliorated by sim fruit extract. Consequently, the movement-defected symptoms were also rescued when the PD fly model was fed with sim fruit extract. Interestingly, SFWE caused no significant difference in fruit flies' development and lifespan, suggesting it's safe to use. Taken together, our results strongly demonstrated that sim fruit, with its high antioxidant content, induced the decline of oxidative stress, and relieved symptoms, which is considered a potential candidate for PD treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.